样式: 排序: IF: - GO 导出 标记为已读
-
Predicting the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Soluble Immune Checkpoints. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-11-20 Aziz Ari,Husnu Sevik,Mert Mahsuni Sevinc,Cihad Tatar,Kenan Buyukasik,Aziz Ahmet Surel,Ufuk Oguz Idiz
Introduction: Personalizing neoadjuvant therapy for locally advanced rectal cancer (LARC) requires identifying biomarkers that predict treatment response. This study aims to evaluate soluble immune checkpoints (sICPs) as predictive markers for neoadjuvant treatment response in LARC patients located in the middle and lower rectum. Materials and Methods: This prospective study included patients diagnosed
-
Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-10-27 Qinwen Li,Xiaoyan Huang,Youfang Zhao
Background: Natural killer (NK) cells are characterized by their antitumor efficacy without previous sensitization, which have attracted attention in tumor immunotherapy. The heterogeneity of osteosarcoma (OS) has hindered therapeutic application of NK cell-based immunotherapy. The authors aimed to construct a novel NK cell-based signature to identify certain OS patients more responsive to immunotherapy
-
The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-10-26 Luca Filippi,Ilaria Proietti,Vincenzo Petrozza,Concetta Potenza,Oreste Bagni,Orazio Schillaci
Background: Baseline 2-deoxy-2[18F]fluoro-d-glucose ([18F]FDG) positron emission tomography (PET)-derived parameters and 12-week metabolic response were investigated as prognostic factors in advanced cutaneous squamous cell carcinoma (cSCC) submitted to cemiplimab immunotherapy. Materials and Methods: Clinical records of 25 cSCC patients receiving cemiplimab, submitted to [18F]FDG positron emission
-
Feasibility of One-Day PET/CT Scanning Protocol with 68Ga-DOTA-FAPI-04 and 18F-FDG for the Detection of Ovarian Cancer Recurrence and Metastasis. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-10-26 Yunuan Liu,Xiaoshan Chen,Fenglian Jing,Xinming Zhao,Zhaoqi Zhang,Jingmian Zhang,Jianfang Wang,Meng Dai,Na Wang,Tingting Wang,Xiaolin Chen
Objective: The objective of this study was to investigate the feasibility of 1-d 68Ga-DOTA-FAPI-04 and 18F-FDG (2-deoxy-2[18F]fluoro-d-glucose) positron emission tomography/computed tomography (PET/CT) for detecting ovarian cancer recurrence and metastasis. Materials and Methods: Fifty-two patients who underwent 18F-FDG and 68Ga-DOTA-FAPI-04 PET/CT were divided into 1- and 2-d groups. Image acquisition
-
NOTCH Signaling Pathway: Occurrence, Mechanism, and NOTCH-Directed Therapy for the Management of Cancer. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-10-05 Lakshmi Kumari,Lopamudra Mishra,Yash Sharma,Kanak Chahar,Mritunjay Kumar,Preeti Patel,Ghanshyam Das Gupta,Balak Das Kurmi
It is now well understood that many signaling pathways are vital in carrying out and controlling essential pro-survival and pro-growth cellular functions. The NOTCH signaling pathway, a highly conserved evolutionary signaling pathway, has been thoroughly studied since the discovery of NOTCH phenotypes about 100 years ago in Drosophila melanogaster. Abnormal NOTCH signaling has been linked to the pathophysiology
-
Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-09-29 Qingjun Zeng,Sanjun Zhang,Linfang He,Qingyan Fu,Li Liao,Linjie Chen,Xiang Ding
Background: Colorectal cancer (CRC) ranks as the third most common cancer, accounting for a significant number of cancer-related deaths worldwide every year. Yet, the molecular mechanisms responsible for the progression of this malignancy are not fully understood. Numerous studies indicate that the BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B) plays a role in the progression of various
-
-
Triangle of Trust in Cancer Care? The Physician, the Patient, and Artificial Intelligence Chatbot. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-09-14 J Harvey Turner
Trust, as a philosophic paradigm, is predominantly interpersonal, between human beings, and is differentiated from reliance. Can a person trust an inhumane amoral agent, such as a large language model artificial intelligence (AI) chatbot, to manifest the goodwill and willingness normally required in order for it to be deemed trustworthy? This article explores the relationship between the cancer patient
-
Recent Advances in Antitumor Dendritic Cell Vaccines. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-09-01 Chunxia Ge,Xuelian Yang,Jiaxuan Xin,Xiangqian Gong,Xuhan Wang,Lijun Kong
Background: Dendritic cells (DCs) are the most important antigen-presenting cells in the body and play a key role in antigen recognition, uptake, processing, and presentation and mediate nonspecific immunity and specific immunity. Purpose: To summarize the main findings that DC vaccines are a new immunotherapy scheme combining the strengths of tumor antigens and DCs that can boost the body's identification
-
A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-08-22 Jian Wang,Li Jiang,Zhenhua Shang,Zhaohua Ye,Dan Yuan,Xin Cui
Background: DNA damage response (DDR) mutation-related genes and composition of immune cells are core factors affecting the effectiveness of immune checkpoint inhibitor therapy. The aim of this study is to combine DDR with immune-related genes to screen the prognostic signature for prostate cancer (PCa). Methods: Gene expression profile and somatic mutation were downloaded from The Cancer Genome Atlas
-
Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-08-16 Aman Mourya,Navnit Prajapati
Cancer chemotherapy has been shifted from conventional cytotoxic drug therapy to selective and target-specific therapy after the findings about DNA changes and proteins that are responsible for cancer. A large number of newer drugs were discovered as targeted therapy for particular types of neoplastic disease. The initial discovery includes the development of the first in the category, imatinib, a
-
Synthesis and Radiolabeling of Glu-Urea-Lys with 99mTc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-08-07 Dara Hatamabadi,Safura Joukar,Pegah Shakeri,Saeed Balalaie,Abdolreza Yazdani,Mona Khoramjouy,Seyed Mohammad Mazidi,Farzad Kobarfard,Mona Mosayebnia,Negar Bozorgchami,Mahnaz Ahmadi,Seyed Mohammad Ayyoubzadeh,Soraya Shahhosseini
Background: The Glu-Urea-Lys (EUK) pharmacophore as prostate-specific membrane antigen (PSMA)-targeted ligand was synthesized, radiolabeled with 99mTc-tricarbonyl-imidazole-BPS chelation system, and biological activities were evaluated. The strategy [2 + 1] ligand is applied for tricarbonyl labeling. (5-imidazole-1-yl)pentanoic acid as a monodentate ligand and bathophenanthroline disulfonate (BPS)
-
4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-07-11 Xiaoling Shen,Rusong Zhang,Xiaojuan Nie,Yanhua Yang,Ye Hua,Peng Lü
4-1BB (CD137, TNFRSF9) is a type I transmembrane protein which binds its natural ligand, 4-1BBL. This interaction has been exploited to improve cancer immunotherapy. With ligand binding by 4-1BB, the nuclear factor-kappa B signaling pathway is activated, which results in transcription of corresponding genes such as interleukin-2 and interferon-γ, as well as the induction of T cell proliferation and
-
Cancer Care by Committee to be Superseded by Personal Physician-Patient Partnership Informed by Artificial Intelligence. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-06-27 J Harvey Turner
Multidisciplinary tumor boards (MTBs) have become the reference standard of cancer management, founded upon randomized controlled trial (RCT) evidence-based guidelines. The inordinate delays inherent in awaiting formal regulatory agency approvals of novel therapeutic agents, and the rigidities and nongeneralizability of this regimented approach, often deny cancer patients timely access to effective
-
Comparison of Whole-Body Dosimetry Measurements in 131I Therapy Using Ceiling-Mounted Geiger-Müller Detectors and γ-Camera Scans: An Agreement Analysis. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-06-26 Nathaly Barbosa,Franklin Niño,María Teresa Vallejo-Ortega,Mónica Naranjo,Carlos Eduardo Granados
Background: In 131I therapies internal dosimetry is crucial for determining the mean absorbed dose to organs at risk, particularly the bone marrow, which has a dose constraint of 2 Gy. Traditionally, multicompartmental models have been used for bone marrow dosimetry, necessitating whole-body absorbed-dose assessments. However, noninvasive techniques, such as γ-camera scans or ceiling-mounted Geiger-Müller
-
Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-05-29 Shan Huang,Ling Ren,Jessica A Beck,Tim E Phelps,Colleen Olkowski,Anita Ton,Jyoti Roy,Margaret E White,Stephen Adler,Karen Wong,Aswini Cherukuri,Xiang Zhang,Falguni Basuli,Peter L Choyke,Elaine M Jagoda,Amy K LeBlanc
Background: Osteosarcoma (OS) is an aggressive pediatric cancer with unmet therapeutic needs. Glutaminase 1 (GLS1) inhibition, alone and in combination with metformin, disrupts the bioenergetic demands of tumor progression and metastasis, showing promise for clinical translation. Materials and Methods: Three positron emission tomography (PET) clinical imaging agents, [18F]fluoro-2-deoxy-2-D-glucose
-
-
A Novel Prognostic Biomarker CCR8 for Gastric Cancer and Anti-CCR8 Blockade Attenuate the Immunosuppressive Capacity of Tregs In Vitro. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-26 Zhigang Zhang,Guoqing Wang,Xiangyu Shao,Hailu Wu,Xiangyu Su,Long Zhu,Zhenling Ji
Objective: To investigate the immunotherapeutic roles and functions of C-C Motif Chemokine Receptor 8 (CCR8) molecule in gastric cancer (GC). Materials and Methods: Clinicopathological features of 95 GC cases were collected by a follow-up survey. The expression level of CCR8 was measured by immunohistochemistry (IHC) staining and analyzed with the cancer genome atlas database. The relationship between
-
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-25 Andrea Bianchi,Maria Luisa De Rimini,Rosa Sciuto,Alessio Annovazzi,Silvia Di Traglia,Matteo Bauckneht,Francesco Lanfranchi,Silvia Morbelli,Anna Giulia Nappi,Cristina Ferrari,Giuseppe Rubini,Stefano Panareo,Luca Urso,Mirco Bartolomei,Davide D'Arienzo,Tullio Valente,Virginia Rossetti,Paola Caroli,Federica Matteucci,Demetrio Aricò,Michelangelo Bombaci,Domenica Caponnetto,Francesco Bertagna,Domenico Albano
Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Materials and Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients
-
Validation of In-House Kit-Like Synthesis of 68Ga-Trivehexin and Its Biodistribution for Targeting the Integrin αvβ6 Expressing Tumors. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-21 Parul Thakral,Subha Shankar Das,Shweta Dhiman,Divya Manda,C B Virupakshappa,Dharmender Malik,Ishita Sen
Background: Integrin αvβ6 has become an extremely promising theranostic target for precise delineation of fast-growing malignant cells in the recent years. The aim of the study was to validate the in-house kit-like synthesis of 68Ga-Trivehexin (integrin αvβ6) and to evaluate its uptake in patients with integrin αvβ6 expressing head and neck and pancreatic cancer. Materials and Methods: 68Ga-Trivehexin
-
Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-05 Ian R Marsh,Chunrong Li,Joseph Grudzinski,Justin Jeffery,Colin Longhurst,David P Adam,Reinier Hernandez,Jamey P Weichert,Paul M Harari,Bryan P Bednarz
Background: Delivery of radiotherapeutic dose to recurrent head and neck cancer (HNC) is primarily limited by locoregional toxicity in conventional radiotherapy. As such, HNC patients stand to benefit from the conformal targeting of primary and remnant disease achievable with radiopharmaceutical therapies. In this study, the authors investigated the tumor targeting capacity of 131I-CLR1404 (iopofosine
-
Neutron Capture Therapy: The Promise of Novel Agents and Medical Facility-Based Neutron Sources. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-01 Jacek Capala,Julie A Hong,Bhadrasain Vikram,C Norman Coleman
-
Strategic Clinical Trial Design for Boron Neutron Capture Therapy. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-04-01 Andrea Wittig,Wolfgang A G Sauerwein
Boron neutron capture therapy (BNCT) involves infusion of cancer patients with a tumor-seeking, boron-loaded compound and irradiation by a beam of neutrons, with an energy range of 1 eV-10 keV. Neutron capture in the 10B atoms results in an effective lethal radiation dose to the tumor cells, while sparing the healthy tissue. Recently available accelerator-based irradiation facilities facilitate developing
-
Immunotherapy for Cancer: Something Old, Something New. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-21 Luca Filippi,Martin W Brechbiel
-
Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-02 Egesta Lopci, Angelo Castello, Luca Filippi
In the past decade, the implementation of immunotherapy with checkpoint inhibitors has determined a major change in the management of oncological patients. The challenges associated to the new therapeutic regimen have promoted adapted criteria for response assessment to interpret imaging findings and atypical patterns of response. Parallel to the new morphological criteria, also 18fluoro-deoxyglucose
-
Philosophy of Cancer Theranostics Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 J. Harvey Turner
Imagine a theranostic nuclear physician oncologist engaged in a Socratic philosophic dialogue. Questions that may be posed include the status of our current knowledge base of radiomolecular tumor biology, the meaning of precision in personalized dosimetry, the nature of responsibility for direct patient care, and the moral and ethical dimensions of individual quality of life (QOL) when survival is
-
Feasibility of 18F-FDG Labelling of Leucocytes in a Centre Without an On-Site Cyclotron and Monitoring of Radiation Dose to Occupational Worker in the Labelling Procedure Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Parul Thakral, Divya Manda, Subha Shankar Das, Pankaj Tandon, Virupakshappa CB, Dharmender Malik, Ishita Sen
Objectives: Differentiation of infection from sterile inflammation is still a major concern for clinicians. The 18F-WBC positron emission tomography/computed tomography scan has been considered a promising tool for accurate diagnosis of infection owing to its high specificity, but it renders the availability of a medical cyclotron a necessity. The aim of the present study was to determine the feasibility
-
Radiochemical Quality Control Methods for Radium-223 and Thorium-227 Radiotherapies Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Abbie Hasson, Wen Jiang, Nadia Benabdallah, Peng Lu, Mark S. Longtine, Bradley J. Beattie, Lucy Summer, Hanwen Zhang, Richard L. Wahl, Diane S. Abou, Daniel L.J. Thorek
Background: The majority of radiopharmaceuticals for use in disease detection and targeted treatment undergo a single radioactive transition (decay) to reach a stable ground state. Complex emitters, which produce a series of daughter radionuclides, are emerging as novel radiopharmaceuticals. The need for validation of chemical and radiopurity with such agents using common quality control instrumentation
-
First-In-Human Pilot PET Immunoimaging Study of 64Cu-Anti-Carcinoembryonic Antigen Monoclonal Antibody (hT84.66-M5A) in Patients with Carcinoembryonic Antigen-Producing Cancers Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Jeffrey Y.C. Wong, David M. Yamauchi, Vikram Adhikarla, Jennifer Simpson, Paul H. Frankel, Yuman Fong, Kurt A. Melstrom, Yi-jen Chen, Behrooz D. Salehian, Yanghee Woo, Savita V. Dandapani, David M. Colcher, Erasmus K. Poku, Paul J. Yazaki, Anna M. Wu, John E. Shively
Background: PET imaging using radiolabeled immunoconstructs shows promise in cancer detection and in assessing tumor response to therapies. The authors report the first-in-human pilot study evaluating M5A, a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb), radiolabeled with 64Cu in patients with CEA-expressing malignancies. The purpose of this pilot study was to identify the
-
68Ga-Labeled Trastuzumab Fragments for ImmunoPET Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Solid Cancers Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Shishu Kant Suman, Archana Mukherjee, Usha Pandey, Avik Chakraborty, Sutapa Rakshit, Megha Tawate, Haladhar Dev Sarma
Background: Trastuzumab, the first humanized antibody approved for therapeutic use has shown promising results for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive cancers. The aim of this study was to formulate immunoPET agents based on trastuzumab fragments and demonstrate their potential for early diagnosis of HER2-positive tumors.
-
18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Yanina Dockx, Christel Vangestel, Sven De Bruycker, Tim Van den Wyngaert, Manon Huizing, Steven Staelens, Sigrid Stroobants
Background: To evaluate 18F-fluoro-2-deoxy-glucose (18F-FDG) and 18F-fluorothymidine (18F-FLT) as early-response biomarkers for phosphoinositide-3-kinase/Akt/mammalian-target-of-rapamycin (PI3K/Akt/mTOR) inhibition in breast cancer (BC) models.
-
Exosome-Mediated Transfer of circ-GLIS3 Enhances Temozolomide Resistance in Glioma Cells Through the miR-548m/MED31 Axis Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Guowei Li, Qing Lan
Background: Temozolomide (TMZ) resistance plays a critical role in the treatment of glioma. This research explored how circRNAs affect the chemosensitivity of glioma cells.
-
64Cu-/177Lu-Cetuximab Theranostic Pair: May the Single 64Cu-Cetuximab Diagnostic Scan Be Acquired at Any Time After Injection? Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-02-01 Eric Laffon, Roger Marthan
Two independent equations were recently proposed for estimating 177Lu-cetuximab cumulative activity, in a preclinical situation, from an initial 64Cu-cetuximab diagnostic scan acquired at peak time of decay-uncorrected (tpeak-uncorr) or decay-corrected (tpeak-corr) time–activity curve of trapped 64Cu-cetuximab, respectively. The standard uptake ratio (SUR) measured at tpeak-uncorr or tpeak-corr turned
-
[18F]FDG PET/CT in a Case of Mycosis Fungoides Showing an Unusual Adverse Reaction to Mogamulizumab: Correlation Between Imaging and Histological Findings Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-01-27 Luca Filippi, Ilaria Proietti, Vincenzo Petrozza, Sara Aversa, Francesco Fiorentino, Concetta Potenza, Oreste Bagni, Orazio Schillaci, Maria Cantonetti
A 73-year-old female patient, affected by mycosis fungoides (MF), discontinued mogamulizumab, after initial clinical benefit, due to the onset of generalized erythema. Follow-up positron emission computed tomography (PET/CTs) carried out at 3 weeks and 6 months after therapy discontinuation showed, with respect to baseline PET/CT scan, a progressively increasing number of hypermetabolic enlarged lymph
-
-
First-, Second-, and Third-Generation Radiolabeled Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Positron Emission Tomography: State of the Art, a Systematic Review Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-01-09 Marko Magdi Abdou Sidrak, Maria Silvia De Feo, Viviana Frantellizzi, Andrea Marongiu, Salvatore Caponnetto, Luca Filippi, Susanna Nuvoli, Angela Spanu, Orazio Schillaci, Giuseppe De Vincentis
Introduction: Lung cancer (LC) is a leading cause of death among men and women, with non-small cell LC (NSCLC) accounting for a substantial portion of the histopathological spectrum and epidermal growth factor receptor (EGFR) mutations being correlated with its manifestation and evolution. Positron emission tomography (PET)/computed tomography has been the most widely used instrument to assess and
-
Aptamer-Based Immunotheranostic Strategies Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-01-05 María Fernanda García Melián, María Moreno, Hugo Cerecetto, Victoria Calzada
The escape from immune surveillance is a hallmark of cancer progression. The classic immune checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, TIM-3 novel ones are part of a sophisticated system of up- and downmodulation of the immune system, which is unregulated in cancer. In recent years, there have been remarkable advances in the development of targeting strategies, focused principally on immunotherapies
-
Reporting Dose in Boron Neutron Capture Therapy Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-01-03 Wolfgang A.G. Sauerwein
Reporting needs uniformity in definitions and terminology. This is crucial in order to be able to compare and aggregate clinical outcomes data across clinical trials. For decades, there is no standard for reporting dose in boron neutron capture therapy (BNCT). Multiple efforts were made for a common language reporting BNCT, mostly suggesting to report at relevant points the different dose components
-
Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2023-01-02 Khalil Ramdhani, Maarten L.J. Smits, Marnix G.E.H. Lam, Arthur J.A.T. Braat
Background: Immunotherapy in the form of checkpoint inhibitors has changed the treatment paradigm in oncology. Combining selective internal radiation therapy (SIRT) with immunotherapy has been suggested to potentially improve outcomes in hepatocellular carcinoma (HCC) and metastatic colorectal carcinoma (mCRC). In this systematic review, the authors discuss the current developments and available clinical
-
IL-6 Accelerates the Proliferation and Metastasis of Pancreatic Cancer Cells via the miR-455-5p/IGF-1R Axis Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-30 Yuting Zhang, Huan He, Lanying He, Bing Shi
Background: Pancreatic cancer (PaC) is a highly malignant gastrointestinal tumor with invasive and metastatic characteristics. Interleukin-6 (IL-6), a negative prognostic marker, contributes to PaC progression. However, the mechanism of IL-6 in PaC is not yet fully understood.
-
Overview of Boron Neutron Capture Therapy in 2022 Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-26 Wolfgang A.G. Sauerwein, Miha Ulčar
In April 2022, the National Cancer Institute of the United States organized a 3-day seminar, dedicated to boron neutron capture therapy (BNCT). This short article summarizes a presentation from that event, which is intended to provide an overview of activities currently underway worldwide to make BNCT available for patient treatments. This overview does not claim to be exhaustive but shows a great
-
Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach. Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-23 Antonia Dimitrakopoulou-Strauss,Christos Sachpekidis,Jessica C Hassel,Petros Christopoulos
Immunotherapy with immune checkpoint inhibitors (ICIs) changed the treatment management in several solid metastatic tumors with very poor prognosis, in particular in melanoma stage IV since its introduction in 2011. However, it is not yet fully understood why some patients respond to ICIs and others not, and it is also unclear why melanomas are the most sensitive tumors to ICI treatment. Selection
-
Circ-PGAM1 Enhances Matrine Resistance of Non-Small Cell Lung Cancer via the miR-326/CXCR5 Axis Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-21 Caijun Dong, Liangwei Yang, Guofang Zhao
Background: Circular RNAs (circ-RNAs) have been demonstrated to influence initiation, drug resistance, and metastasis of tumors. However, the effects of circular-phosphoglycerate mutase 1 (circ-PGAM1) on matrine resistance in nonsmall cell lung cancer (NSCLC) remain unknown.
-
Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-20 Ghazal Norouzi, Sara Nikdel, Elahe Pirayesh, Yazdan Salimi, Mahasti Amoui, Hamidreza Haghighatkhah, Mohammad Ali Ghodsi Rad, Elmira Javanijouni, Sepideh Khoshbakht
Purpose: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic hepatic disease worldwide, with functional impairment of the mitochondria occurring from early stages. Technetium-99m methoxy-isobutyl-isonitrile (99mTc-MIBI) is a lipophilic agent trapped in the mitochondria. This study aims to evaluate the utility of 99mTc-MIBI heart/liver uptake ratio in screening for NAFLD during myocardial
-
Matrine Inhibits Proliferation, Invasion, and Migration and Induces Apoptosis of Colorectal Cancer Cells Via miR-10b/PTEN Pathway Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Yun Cheng, Chen Yu, Weibing Li, Yongming He, Yuhua Bao
Background: Colorectal cancer (CRC) is the third most common malignancy worldwide. Matrine can act as a potential antitumor drug, and its antitumor activities have been tested in various cancers, including CRC. However, the effect of matrine and the related mechanisms on CRC cells remains poorly defined.
-
Profiling of Tumor Microenvironment Components Identifies Five Stroma-Related Genes with Prognostic Implications in Colorectal Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Jing-Wen Liu, Fei Yu, Yuan-Fei Tan, Jian-Ping Huo, Zhao Liu, Xiao-Jing Wang, Jian-Ming Li
Background: Tumor microenvironment (TME) significantly affects colorectal cancer (CRC) progression and therapeutic efficacy, particularly the infiltrating stromal components. This study profiled the TME composition of tumor tissue and identify TME-related, especially stroma-related genes having prognosis value in CRC patients.
-
Identification of a Prognostic Colorectal Cancer Model Including LncRNA FOXP4-AS1 and LncRNA BBOX1-AS1 Based on Bioinformatics Analysis Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Zhi-Liang Shi, Guo-Qiang Zhou, Jian Guo, Xiao-Ling Yang, Cheng Yu, Cheng-Long Shen, Xin-Guo Zhu
Background: Knowledge about the prognostic role of long noncoding RNA (lncRNA) in colorectal cancer (CRC) is limited. Therefore, we constructed a lncRNA-related prognostic model based on data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA).
-
Integrated Analysis of Gene Expression and Metabolite Data Reveals Candidate Molecular Markers in Colorectal Carcinoma Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Junsheng Yang, Shan Gao, Meiqing Qiu, Shifeng Kan
Background: This study investigated potential gene targets and metabolite markers associated with colorectal carcinoma (CRC).
-
miR-548a-3p Weakens the Tumorigenesis of Colon Cancer Through Targeting TPX2 Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Ming Wang, Min Yang, Benyuan Deng
Background: MicroRNA (miRNA) has been verified a significant factor to participate in the progression of colon cancer (CC). In this study, the authors investigated the mechanism and function of miR-548a-3p in CC.
-
Downregulation of Long Noncoding RNA Myocardial Infarction Associated Transcript Suppresses Cell Proliferation, Migration, Invasion, and Glycolysis by Regulation of miR-488-3p/IGF1R Pathway in Colorectal Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Yunhua Liu, Huaiying Peng, Yongxiang Shen, Rongfeng Da, Aihua Tian, Xiaomei Guo
Background: Colorectal cancer (CRC) is a significant public problem and the third cause of cancer-induced death all over the world. Long noncoding RNA (lncRNA) has been reported as a vital mediator in human cancer. However, the precise role of lncRNA myocardial infarction associated transcript (MIAT) in CRC is unclear.
-
Clinical Significance of β-Lactamase Expression in Colorectal Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Shaofei Zhou, Lei Miao, Tiantian Li, Pu Liu, Houmin Zhou
Background: Colorectal cancer (CRC) has seriously endangered human health. Despite significant advances in clinical treatment of CRC in recent years, clinically effective treatment options for CRC patients remain rare. Therefore, reducing the incidence and mortality of CRC is still a worldwide concern. This study aims to explore the clinical significance of lactamase beta (LACTB)-like expression in
-
Pulsatilla Decoction Combined with 5-Fluorouracil Triggers Immunogenic Cell Death in Colorectal Cancer Cells Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Yanghua Jie, Xiaobei Yang, Weidong Chen
Background: Our research is designed to explore the role of 5-FU and Pulsatilla decoction (PD) through modulation of Immunogenic cell death (ICD) for the co-treatment of Colorectal cancer (CRC).
-
The Efficacy of Hemoglobin, Albumin, Lymphocytes, and Platelets as a Prognostic Marker for Survival in Octogenarians and Nonagenarians Undergoing Colorectal Cancer Surgery Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Hasan Dagmura, Emin Daldal, Ismail Okan
Objectives: With the aging population worldwide, the octogenarians are becoming a substantial group and since cancer incidence increases by age, this group of patients is becoming more affected. However, no distinct treatment algorithm has been established for elderly patients with cancer. The present study aimed to determine the prognostic value of several inflammatory parameters by comparing octogenarian
-
A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Jingwen Liu, Fei Yu, Zhao Liu, Xiaojing Wang, Jianming Li
Background: Colorectal cancer (CRC) has been a major public health problem. Tumor microenvironment (TME) greatly contributes to the heterogeneity of CRC and is crucial for the regulation of CRC progression. The authors' study aimed to develop a robust prognostic signature for CRC patients based on TME-related genes.
-
Knockdown RBM15 Inhibits Colorectal Cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6A) Modification of MyD88 mRNA Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Zhen Zhang, Yan Mei, Mingxing Hou
Colorectal cancer (CRC) is one of the most common cancers worldwide. In this study, we explored the role of RNA binding motif protein 15 (RBM15)-mediated MyD88 mRNA N6-methyladenosine (m6A) in CRC development. Cell proliferation, apoptosis, and invasion were detected by EdU, Annexin V-FITC/PI staining, and Transwell assays, respectively. RBM15 and MyD88 expression was detected by RT-qPCR and Western
-
TIGD1 Is an Independent Prognostic Factor that Promotes the Progression of Colon Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-12-12 Junwei Zou, Hesong Zhang, Zhaoying Wu, Weichao Hu, Tingting Zhang, Hao Xie, Yong Huang, Hailang Zhou
Background: Trigger transposable element-derived 1 (TIGD1) is a human-specific gene, but no studies have been conducted to determine its mechanism of action. Our aim is to ascertain the function and mode of action of TIGD1 in the development of colon cancer.
-
The Role of N6-Methyladenosine Methylation in the Progression of Endometrial Cancer Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-11-14 Kewei Song, Hongxia Xu, Changhe Wang
Purpose: N6-methyladenosine (m6A) methylation was the most abundant internal modification on messenger RNAs in eukaryotes. This study intended to explore the role of m6A methylation in endometrial cancer (EC).
-
High APOBEC1 Complementation Factor Expression Positively Modulates the Proliferation, Invasion, and Migration of Endometrial Cancer Cells Through Regulating P53/P21 Signaling Pathway Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-11-14 Qin Liu, Chun-Yan Chen, Gui-Lin Chen
Background: APOBEC1 complementation factor (A1CF) is a component of the apolipoprotein-B messenger RNA editing complex that participates in various cellular processes and acts as an oncogene in many cancers. In this study, it was aimed to investigate the roles of A1CF and its potential mechanism in endometrial cancer (EC).
-
Clinical Observation of Double Percutaneous Nephrostomy Combined with Ureter Occlusion Stent for Treating Cervical Cancer Complicated with Vesicovaginal Fistula Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-11-14 Xu-Hua Duan, Feng-Yao Li, Xin-Wei Han, Gang Wu, Jian-Hao Zhang, Yu-Dong Tian, Yan-Cang Zhang
Background: To evaluate the efficacy of double percutaneous nephrostomy (PCN) combined with ureter occlusion stent for treating cervical cancer complicated with vesicovaginal fistula (VVF).
-
Circ_0000745 Promotes the Progression of Cervical Cancer by Regulating miR-409-3p/ATF1 Axis Cancer Biother. Radiopharm. (IF 3.4) Pub Date : 2022-11-14 Xia Cui, Jiming Chen, Yafeng Zheng, Huaji Shen
Background: Cervical cancer (CC) is a common gynecological malignancy with a high risk of recurrence and death. Circular RNAs play a crucial role in the occurrence and development of tumors. This study aimed to investigate the function and mechanism of circ_0000745 in CC.